ZISKA PHARMA: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from ZISKA PHARMA?
Yes. FDA’s import refusal records list 2 refused shipment lines declared as made by ZISKA PHARMA (Bangladesh) whose FDA product code names tirzepatide, from Feb 27, 2025 to May 5, 2026. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Country
- Bangladesh
- City in FDA records
- Dhaka
- FEI numbers on the lines
- 3033003350
- Refused lines
- 2
- Lines with an Import Alert 66-80 API or powder code
- 0
- Drugs named in the product codes
- Tirzepatide
- Refusal dates
- Feb 27, 2025 to May 5, 2026
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether ZISKA PHARMA is on it.
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| May 5, 2026 | Bangladesh | 61PCY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 799-5468269-2/20002/1 |
| Feb 27, 2025 | Bangladesh | 61PDY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | AEK-8210662-4/11/1 |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 2 |
| NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | 1 |
| FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | 1 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.
2 lines from FDA files read Nov 15, 2026.